novidades científicas Novo

16:13 European Cardiovascular Disease Statistics 2017
10:47 CETP inhibitor meets primary endpoint in CV outcome study
9:54 Arrhythmias and devices
14:31 Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial
14:18 Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism

Medical management of peripheral arterial disease – Sergi Bellmunt

25 Outubro 2017

Resumo da apresentação

Apresentação

Sergi Bellmunt
SP

Bioabsorbable stents. What is the next chapter? - Ricardo Santos

18 Outubro 2017
0

Life prolongation in chronic heart failure - John Cleland

1 Novembro 2017
0

-->